S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment

5. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

An American multinational biopharmaceutical company, AbbVie Inc. (NYSE:ABBV) ranks fifth on our list of the best dividend aristocrat stocks. The company reported fourth-quarter revenue of $15.1 billion, reflecting a 5.6% year-over-year increase and exceeding analysts’ estimates of $14.87 billion. On a GAAP basis, the company recorded a net loss of $0.02 per share for the quarter. However, adjusted diluted earnings per share (EPS) stood at $2.16, slightly surpassing the expected $2.13. For 2024, combined sales of Skyrizi and Rinvoq reached $17.7 billion, representing a 51% year-over-year growth, driven by increasing global demand and continued market expansion. Excluding Humira, AbbVie’s total revenue rose 18% from the previous year, supported by strong results in its neuroscience and oncology divisions.

In the past 12 months, AbbVie Inc. (NYSE:ABBV) has surged by over 13%. It is a leading pharmaceutical company with a diverse portfolio spanning immunology, oncology, neuroscience, and eye care. The company also commercializes popular aesthetic treatments, including Botox and Juvederm, for anti-aging skincare. Its commitment to innovation, combined with its broad range of therapies, reinforces its position as a blue-chip stock and a compelling investment opportunity.

On February 13, AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend of $1.64 per share, which was in line with its previous dividend. Overall, the company has been rewarding shareholders with growing dividends for the past 52 years. The stock supports a dividend yield of 3.25%, as of February 23.